|
| Biotinylated Human ALCAM/CD166 Protein (Primary Amine Labeling) (LTP10227) |
|
| LTP10227 |
|
| 100ug |
|
|
$789 In stock |
| Brain metastasis (BM) in non-small-cell lung cancer (NSCLC) has a very poor prognosis. Recent studies have demonstrated the importance of cell adhesion molecules in tumor metastasis.Elevated levels of ALCAM expression promote BM formation in NSCLC through increased tumor cell dissemination and interaction with the brain endothelial cells. Therefore, ALCAM could be targeted to reduce the occurrence of BM. |
| Recombinant Biotinylated Human ALCAM/CD166 Protein (Primary Amine Labeling) is expressed from Expi293 with His tag at the C-terminal. It contains Trp28-Ala526. |
|
| ALCAM/CD166 |
|
| Human |
|
| Q13740-1 |
|
| Trp28-Ala526 |
|
| The protein has a predicted MW of 57 kDa. Due to glycosylation, the protein migrates to 70-80 kDa based on the Tris-Bis PAGE result. |
|
| Immobilized Anti-ALCAM Antibody, hFc Tag at 5ug/ml (100ul/well) on the plate. Dose response curve for Biotinylated Human ALCAM, His Tag with the EC50 of 3.7ug/ml determined by ELISA. See testing image for detail. |
|
| C-His |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
